- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Granules India, NIPER SAS Nagar inaugurate Centre of Excellence for Sustainable Pharma Innovation

Mumbai: Granules India Limited, in partnership with the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S Nagar, has inaugurated the Dr. Chigurupati Centre of Excellence in Innovative and Sustainable Pharmaceutical Development (CCE-ISPD).
This Granules’ CSR initiative aims to empower students and researchers with access to cutting-edge facilities and resources, fostering innovation in eco-friendly solutions for learning pharmaceutical manufacturing.
Speaking at the inauguration, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited, said, “At Granules, we believe that innovation and sustainability go hand in hand. Guided by our purpose of Healing Lives Responsibly through Pioneering Green Science, this initiative reflects our commitment to shaping a healthier, more sustainable future, not only for our stakeholders, but also for the communities and ecosystems that sustain us.”
Prof. Dulal Panda, Director, NIPER S.A.S Nagar, added, "This collaboration brings academia and industry together to solve real-world challenges. By focusing on green cand sustainable practices, we can deliver solutions that benefit both the environment and patients worldwide."
As per the release, the Centre, under the supervision of Dr. Arvind.K Bansal, Professor Department of Pharmaceutics, Lead and Academic Supervisor of the Centre will harness NIPER’s academic and research strengths alongside Granules India’s industrial expertise to develop scalable, eco-friendly solutions for the pharmaceutical sector.
The collaboration will focus on interface between API and formulation manufacturing, reducing the carbon footprint in formulation production, creating intellectual property in sustainable technologies, training next-generation scientists, and setting new industry benchmarks in sustainable manufacturing.
Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. Granules is among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Granules products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 8 are in India and 2 in the USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751